Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN-CLL-322: pirtobrutinib + venetoclax + rituximab versus venetoclax + rituximab in previously treated CLL/SLL
MOH_2021-12-13_010471Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Loxo Oncology. Started Dec 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2021-12-13_010471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-13_010471.